Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2009 Nov 16.

Published in final edited form as: J Immunotoxicol. 2008 Jul;5(3):315–335. doi: 10.1080/15376510802312464

TABLE 2.

Study Schema.

Study designation	Study Type	Product	Dose	Dosing Schedule	Blood Draw Schedule	Necropsy Schedule
A	Biodistribution	14 (HIV-1)	10¹¹ PU	SD1	N/A	SD9, 61, 91
B	Biodistribution	18 (Ebola)	0.89 × 10¹¹ VP	SD1	N/A	SD9, 61, 93
C	Biodistribution	27 (HIV-1)	0.5 × 10¹¹ PU	SD1	N/A	SD9, 91
D	Toxicology	14 (HIV-1)	10¹¹ PU	SD1, 22	PTID ^*, SD3, 24, SD36	SD24, 36
		9, 14 (HIV-1)	4 mg, 10¹¹ PU	SD1, 22, 43, 64 (#9), SD85, 106 (#14)	PTID, SD3, 24, 45, 66, 86, 108, 120	SD108, 120
E	Toxicology	18 (Ebola mut)	2 × 10¹¹ VP	SD1, 22, 43	PTID, SD3, 24, 45, 57	SD45, 57
		22 (Ebola WT)	2 × 10¹¹ VP	SD1, 22, 43	PTID, SD3, 24, 45, 57	SD45, 57
F	Toxicology	25, 21 (Marburg)	4 mg, 10¹¹ VP	SD1, 22, 43, 64 (#25), SD85, 106 (#21)	PTID, SD4, 30, 60, 90, 108, 120	SD108, 120
G	Toxicology	27 (HIV-1)	10¹¹ PU	SD1, 22, 43	PTID, SD4, 30, 45, 57	SD45, 57

^*

PTID = prior to initial dosing